Xention

Develops ion channel-modulating drugs for the treatment of atrial fibrillation, overactive bladder and chronic cough.

placeCambridge, England, United Kingdom calendar_todayFounded 2002 groups13 employees language xention.com

Registered entities

Innovation

27 patent families (19 granted) — focus: Chemistry & metallurgy, Physics & computing, Human necessities; filing pace dormant. Cited 3,452 times.

YearFilings
201210
20137
20145
20156
20162
20172
20181
20191

Investor mix

15 investors on record; lead investors include Seroba Life Sciences, BTG International.

Investor typeCountShare
Venture capital213%
Private equity427%
Bank & private debt17%
Other / undisclosed853%
Coming soon